Open AccessDurvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
Author(s) -
Jaseela Chiramel,
Rebecca Tay,
Raffaele Califano
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.04.29
Subject(s) - medicine , durvalumab , lung cancer , radiation therapy , stage (stratigraphy) , oncology , cancer , lung , disease , pathology , immunotherapy , paleontology , nivolumab , biology
Lung cancer is the most common cause of death worldwide. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and a third of NSCLC patients present with unresectable locally advanced disease (1).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom